Atlas Trials

Ficlatuzumab w/wo Cetuximab in Patients w/Cetuximab-Resistant, Recurrent or Metastatic Head/Neck Squamous Cell Carcinoma

Clinical trial NCT03422536 · COMPLETED

Trial details

NCT number
NCT03422536
Sponsor
University of Arizona
Status
COMPLETED
Phase
Phase 2
Study type
INTERVENTIONAL
Head and Neck Basaloid CarcinomaRecurrent Head and Neck Squamous Cell CarcinomaRecurrent Oropharyngeal Squamous Cell CarcinomaSquamous Cell Carcinoma of Unknown Primary OriginStage IV Squamous Cell Carcinoma of the Lip and Oral CavityStage IV Squamous Cell Carcinoma of the Paranasal Sinus and Nasal CavityStage IV Nasopharyngeal Keratinizing Squamous Cell CarcinomaStage IV Oropharyngeal Squamous Cell CarcinomaStage IVA Lip and Oral Cavity Squamous Cell CarcinomaStage IVA Nasal Cavity and Paranasal Sinus Squamous Cell CarcinomaStage IVA Nasopharyngeal Keratinizing Squamous Cell CarcinomaStage IVA Oropharyngeal Squamous Cell Carcinoma
Start date
2017-12-05
Primary completion
2022-03-29
Enrollment
78

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.